Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
On 30 April 2026, Axsome Therapeutics announced the FDA approval of Auvelity (dextromethorphan + bupropion) for the treatment of agitation…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
Low patient accrual continues to hinder male infertility trials
Male infertility can be caused by numerous lifestyle factors, including poor lifestyle, genetic factors, or specific drug treatments such as…
-
Meta-analysis backs broader use of BP therapy in CKD
A recent study conducted by Guyu Zeng and colleagues and published in The Lancet highlighted that lowering blood pressure (BP)…
-
Study finds dose-response relationship between gestational age and autism risk
April is Autism Awareness Month, dedicated to increasing understanding, broadening opportunities, and creating change for people with autism spectrum disorder…
-
Malaria vector Anopheles (Nyssorhynchus) darlingi evolving insecticide resistance
Malaria is a bloodborne parasitic disease wherein Plasmodium parasites are transmitted by mosquito vectors. Despite efforts to control mosquito populations,…
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir,…
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results…
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial…
-
ESCMID Global 2026: Olorofim targets invasive Aspergillus in hematology patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference in Munich, Germany, data on F2G’s…
-
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, BlueRock Therapeutics, a wholly owned, independently operated subsidiary…